Stereotactic ablative radiotherapy (SABR) is a form of external beam radiotherapy that accurately delivers a high dose of irradiation in one or few fractions to extracranial tumors. Studies have shown SABR to be safe and effective for treating oligometastatic prostate cancer lesions, with low toxicity and good local tumor control. However, larger trials like STOMP and ORIOLE that compared SABR to surveillance found no reduction in metastatic progression, possibly due to limitations in accounting for disease aggressiveness between treatment groups. SABR remains a promising option for select oligometastatic prostate cancer patients.